Wetzels JFM - Search Results

1

Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy.

Vink CH, van Cranenbroek B, van der Heijden JW, Koenen HPJM, Wetzels JFM. Vink CH, et al. Among authors: wetzels jfm. Kidney Int. 2022 Mar;101(3):646-647. doi: 10.1016/j.kint.2021.12.019. Kidney Int. 2022. PMID: 35190038 No abstract available.

2

The bias between different albumin assays may affect clinical decision-making.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M. van de Logt AE, et al. Kidney Int. 2019 Jun;95(6):1514-1517. doi: 10.1016/j.kint.2019.01.042. Epub 2019 Feb 27. Kidney Int. 2019. PMID: 31053386 Free article.

3

COVID-19 Vaccination in Patients With Membranous Nephropathy.

Visch R, Wetzels J, Vink C, van de Logt AE. Visch R, et al. Kidney Int Rep. 2022 Aug;7(8):1922-1923. doi: 10.1016/j.ekir.2022.05.038. Epub 2022 Jun 9. Kidney Int Rep. 2022. PMID: 35702396 Free PMC article. No abstract available.

4

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal.

Duineveld C, Bouwmeester R, van der Heijden JW, Berger SP, van de Kar NCAJ, Wetzels JFM; Dutch aHUS Working Group. Duineveld C, et al. Among authors: wetzels jfm. Clin Kidney J. 2020 Dec 15;14(8):1939-1945. doi: 10.1093/ckj/sfaa241. eCollection 2021 Aug. Clin Kidney J. 2020. PMID: 34631043 Free PMC article.

5

The authors reply.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M. van de Logt AE, et al. Kidney Int. 2019 Jul;96(1):249. doi: 10.1016/j.kint.2019.04.008. Kidney Int. 2019. PMID: 31229039 Free article. No abstract available.

6

Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy.

Logt AV, Justino J, Vink CH, van den Brand J, Debiec H, Lambeau G, Wetzels JF. Logt AV, et al. Kidney Int Rep. 2021 Apr 22;6(6):1677-1686. doi: 10.1016/j.ekir.2021.04.002. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169209 Free PMC article.

7

Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.

van de Logt AE, Hofstra JM, Wetzels JF. van de Logt AE, et al. Kidney Int. 2015 Jun;87(6):1263-4. doi: 10.1038/ki.2015.34. Kidney Int. 2015. PMID: 26024039 Free article. No abstract available.

8

Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?

Hofstra JM, Wetzels JFM. Hofstra JM, et al. Among authors: wetzels jfm. Kidney Int. 2016 May;89(5):981-983. doi: 10.1016/j.kint.2016.01.019. Kidney Int. 2016. PMID: 27083274 Free article.

9

The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.

van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. van de Logt AE, et al. Kidney Int. 2019 Dec;96(6):1292-1302. doi: 10.1016/j.kint.2019.07.014. Epub 2019 Aug 12. Kidney Int. 2019. PMID: 31611068 Free article. Review.

10

Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.

van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J. van de Logt AE, et al. Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019. Kidney Int. 2018. PMID: 29571438 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

574 results

Search Page

Filters